Pre-market hot trades in US stocks: Harrison Global pre-market down 10.64%; SEALSQ pre-market up 9.30%

Tracking Unusual Activity
2025.10.20 09:08
portai
I'm PortAI, I can summarize articles.

Harrison Global pre-market down 10.64%; SEALSQ pre-market up 9.30%; Beyond Meat pre-market up 70.38%; FGI Industries pre-market up 56.30%; Celcuity pre-market up 50.94%

Popular Pre-Market Trades in US Stocks

Harrison Global, down 10.64% in pre-market trading, has no significant news recently. Trading is active with clear capital flow, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

SEALSQ is up 9.30% in pre-market trading. According to recent important news:

  1. On October 17, Sealsq announced its integration strategy involving its recent acquisition of the French ASIC design company IC’Alps. This plan positions Sealsq as the only company capable of providing secure hardware solutions ranging from Catalog ICs to Custom ICs and Security IP. This news drove its stock price up 10.2% in pre-market trading. Data source: NASDAQ:LAES. The trend of consolidation in the semiconductor industry is evident, with a focus on the era of quantification.

Top Gainers in Pre-Market Trading in US Stocks

Beyond Meat is up 70.38% in pre-market trading. According to recent important news:

  1. On October 16, Beyond Meat announced the lifting of the lock-up restriction on 316,150,176 new shares. This news sparked market expectations for increased liquidity of the company's stock, leading to a significant price surge.

  2. On October 17, investors took a bearish stance on Beyond Meat, reflected in the publicly available options trading history, indicating market concerns about the company's future performance.

  3. No other significant news recently. Market volatility is high, and risks should be monitored.

FGI Industries is up 56.30% in pre-market trading, with no significant news recently. Trading is active with clear capital flow, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

Celcuity is up 50.94% in pre-market trading. According to recent news:

  1. On October 18, Celcuity announced the initiation of a rolling new drug application submission, expected to be completed in the fourth quarter of 2025. This news significantly boosted the stock price.

  2. On October 18, Celcuity released clinical trial results for the PIK3CA mutation cohort, showing that gedatolisib combination therapy significantly improved progression-free survival in breast cancer patients and reduced the risk of disease progression or death.

  3. On October 18, Celcuity presented clinical data on the combination therapy of gedatolisib and Nubeqa® at the European Society for Medical Oncology (ESMO) conference, demonstrating positive efficacy for mCRPC patients. The biotechnology industry has shown strong recent performance, with significant capital inflow

Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.